Pre-clinical trials in mice with MSS CRC [78] showed that altering the gut microbiome using antibiotics blunted the response to anti-PD1 inhibitors, while Lactobacillus adiophilus lysates enhanced the efficacy of anti-CTLA4 inhibitors [79]. Here, CTLA4 is linked to colorectal carcinoma.